{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:49:05Z","timestamp":1778802545972,"version":"3.51.4"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"12","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA180868"],"award-info":[{"award-number":["U10 CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA180822"],"award-info":[{"award-number":["U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>We assessed the efficacy of anti\u2013PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior bevacizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>NRG-GY023 was the first randomized four-arm superiority phase II trial enrolling patients with high-grade serous\/endometrioid or clear-cell PROC with prior bevacizumab exposure. Patients were randomized 1:2:2:2 to SOC (weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin), DOC, durvalumab + cediranib (DC), or olaparib + cediranib (OC). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, overall response rate, and safety. The design had 80% power to detect an HR of 0.5 using a one-sided, \u03b1 = 0.1-level test for each comparison with the SOC with a preplanned interim analysis. Experimental arms with HR estimates (vs. SOC) &amp;gt;0.87 could be discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 153 patients were enrolled between April 4, 2021, and February 1, 2023. Accrual was permanently closed on February 1, 2023, due to futility. With a data cutoff of September 9, 2024, the median PFS was 3.4, 2.9, 2.5, and 2.8 months, and median overall survival was 7.5, 8.3, 5.7, and 10.2 months for SOC, DOC, DC, and OC, respectively. The overall response rate was 4.3% [95% confidence interval (CI), 0.00\u20130.19], 15.9% (95% CI, 0.07\u20130.29), 11.9% (95% CI, 0.05\u20130.24), and 9.1% (95% CI, 0.03\u20130.20) for SOC, DOC, DC, and OC, respectively. Compared with SOC, the PFS HR estimates were 1.003 (95% CI, 0.56\u20131.80), 1.108 (95% CI, 0.63\u20131.96), and 1.021 (95% CI, 0.57\u20131.82) for DOC, DC, and OC, respectively. No new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with PROC with prior bevacizumab, all experimental arms failed to reach the primary objective of improving PFS compared with SOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-24-3877","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T10:59:32Z","timestamp":1744023572000},"page":"2370-2378","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial"],"prefix":"10.1158","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1280-5909","authenticated-orcid":false,"given":"Jung-Min","family":"Lee","sequence":"first","affiliation":[{"name":"1Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland."}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9739-8462","authenticated-orcid":false,"given":"Austin","family":"Miller","sequence":"additional","affiliation":[{"name":"2NRG Oncology, Clinical Trial Development Division, Department Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York."}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2676-0166","authenticated-orcid":false,"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[{"name":"3Department of Surgery, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio."},{"name":"4Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-5591","authenticated-orcid":false,"given":"Mariam","family":"AlHilli","sequence":"additional","affiliation":[{"name":"3Department of Surgery, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio."},{"name":"4Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-8860","authenticated-orcid":false,"given":"Christina","family":"Washington","sequence":"additional","affiliation":[{"name":"5Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2688-5447","authenticated-orcid":false,"given":"Veena S.","family":"John","sequence":"additional","affiliation":[{"name":"6Gynecologic Oncology, Northwell Health, New Hyde Park, New York."}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4372-2614","authenticated-orcid":false,"given":"Chirag A.","family":"Shah","sequence":"additional","affiliation":[{"name":"7Gynecologic Oncology, Pacific Cancer Research Consortium, Seattle, Washington."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8701","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[{"name":"8Gynecologic Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-3634","authenticated-orcid":false,"given":"Jean","family":"Siedel","sequence":"additional","affiliation":[{"name":"9Gynecological Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-5887","authenticated-orcid":false,"given":"David S.","family":"Miller","sequence":"additional","affiliation":[{"name":"10Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, Texas."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-0501","authenticated-orcid":false,"given":"Elizabeth E.","family":"Hopp","sequence":"additional","affiliation":[{"name":"11Gynecologic Oncology, Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin."}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3829-3988","authenticated-orcid":false,"given":"Andrea","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"12Gynecologic Oncology, University of Minnesota, Metro Minnesota Community Oncology Research Consortium, Minneapolis, Minnesota."}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3379-6829","authenticated-orcid":false,"given":"John K.","family":"Chan","sequence":"additional","affiliation":[{"name":"13Gynecologic Oncology, Sutter Cancer Research Consortium, San Francisco, California."}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-6712","authenticated-orcid":false,"given":"Leslie S.","family":"Bradford","sequence":"additional","affiliation":[{"name":"14Gynecologic Oncology, MaineHealth Cancer Care Network, Scarborough, Maine."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0155-4246","authenticated-orcid":false,"given":"Christopher B.","family":"Morse","sequence":"additional","affiliation":[{"name":"15Obstetrics and Gynecology, Allegheny General Hospital, Pittsburgh, Pennsylvania."}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6454-6246","authenticated-orcid":false,"given":"Christa I.","family":"Nagel","sequence":"additional","affiliation":[{"name":"16Division of Gynecologic Oncology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8884-7083","authenticated-orcid":false,"given":"Kerry J.","family":"Rodabaugh","sequence":"additional","affiliation":[{"name":"17Gynecologic Oncology, Fred & Pamela Buffett Cancer Center - Nebraska Medical Center, Omaha, Nebraska."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-9762","authenticated-orcid":false,"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[{"name":"18Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland."}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[{"name":"5Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma."}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-3972","authenticated-orcid":false,"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[{"name":"19Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts."}]}],"member":"1086","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"2025061304145189600_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.23.01771","article-title":"Treatment approaches for platinum-resistant ovarian cancer","volume":"10","author":"St Laurent","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025061304145189600_bib2","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025061304145189600_bib3","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"2025061304145189600_bib4","doi-asserted-by":"crossref","first-page":"102546","DOI":"10.1016\/j.ctrv.2023.102546","article-title":"The evolving landscape of antibody-drug conjugates in gynecologic cancers","volume":"116","author":"Tolcher","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2025061304145189600_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025061304145189600_bib6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","article-title":"Heterogeneity and treatment landscape of ovarian carcinoma","volume":"20","author":"Veneziani","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025061304145189600_bib7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2025061304145189600_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025061304145189600_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/jcm8030380","article-title":"Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets","volume":"8","author":"Napoletano","year":"2019","journal-title":"J Clin Med"},{"key":"2025061304145189600_bib10","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1\u20133 inhibitor cediranib in women\u2019s cancers: a dose-escalation, phase I study","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025061304145189600_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2024.05.002","article-title":"A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib","volume":"187","author":"Liu","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025061304145189600_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025061304145189600_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"},{"key":"2025061304145189600_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"2025061304145189600_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2025061304145189600_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2025061304145189600_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"key":"2025061304145189600_bib18","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025061304145189600_bib19","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1200\/JCO.24.00683","article-title":"Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025061304145189600_bib20","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025061304145189600_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/1078-0432.CCR-23-0771","article-title":"Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T\/MINOVA study)","volume":"30","author":"Tavira","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025061304145189600_bib22","doi-asserted-by":"crossref","first-page":"16025","DOI":"10.1038\/cddiscovery.2016.25","article-title":"Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients","volume":"2","author":"Martino","year":"2016","journal-title":"Cell Death Discov"},{"key":"2025061304145189600_bib23","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2025061304145189600_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2020.07.031","article-title":"Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2025061304145189600_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2019.03.246","article-title":"Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer","volume":"153","author":"Secord","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025061304145189600_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025061304145189600_bib27","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","article-title":"Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study","volume":"26","author":"Lampert","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025061304145189600_bib28","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group","volume":"15","author":"Freyer","year":"2024","journal-title":"Nat Commun"},{"key":"2025061304145189600_bib29","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J Leukoc Biol"},{"key":"2025061304145189600_bib30","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-21-1733","article-title":"Cediranib in combination with olaparib in patients without a germline BRCA1\/2 mutation and with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025061304145189600_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"2025061304145189600_bib32","doi-asserted-by":"crossref","first-page":"e2300693","DOI":"10.1200\/PO.23.00693","article-title":"Niraparib, dostarlimab, and bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort A of the OPAL phase II trial","volume":"8","author":"Liu","year":"2024","journal-title":"JCO Precis Oncol"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-24-3877\/3568930\/ccr-24-3877.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-24-3877\/3600380\/ccr-24-3877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/31\/12\/2370\/3611527\/ccr-24-3877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/31\/12\/2370\/3611527\/ccr-24-3877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:15:08Z","timestamp":1749788108000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/31\/12\/2370\/762778\/Comparing-Durvalumab-Olaparib-and-Cediranib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,4,7]]},"published-print":{"date-parts":[[2025,6,13]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-24-3877","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.29313367","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29313361","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29313373","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29313364","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29313370","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.29313358","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.7873843","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}